Goldman Sachs: Pharmaron Beijing's (02268.HK) order momentum continues to be strong with a target price of 63.3 Hong Kong dollars.

According to the WiseFinancial APP, Goldman Sachs released a research report stating that the order momentum of Wuxi Biologics (02268.HK) remains strong, with steady customer demand, especially from American customers. The exploration outside the ADC (antibody-drug conjugates) field continues to be active, such as AOC (antibody oligonucleotide conjugates) and RDC (radioactive isotope conjugates). The target of a 45% year-on-year revenue growth for the whole year is progressing as expected. In addition, the company is actively negotiating contracts with customers for the Singapore plant, and is expected to sign several contracts by the end of the year. However, due to the need for capacity expansion, the revenue contribution from the plant before 2027 is expected to be limited. The rest of the capacity and personnel expansion are also progressing as planned, with recruitment ongoing. The target price is set at 63.3 Hong Kong dollars.